About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety and Efficacy of WIN-901X in Asthma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01820481

Safety and Efficacy of WIN-901X in Asthma

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

Lead sponsor: Whanin Pharmaceutical Company•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Whanin Pharmaceutical Company

Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients

Age

20 - 79 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Greater than or equal to 20 and less than 80 years of age
•Have physician diagnosed asthma with irreversible airway obstruction at least 6 months prior to the screening
•FEV1 between 60% and 85% before inhaling fast-acting bronchodilator at screening
•No history of smoking at least one year prior to the screening
•Having voluntarily signed an informed consent

Exclusion Criteria

•Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening
•Have been hospitalized due to an acute worsening of asthma within 3 months before the screening
•Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract infection, and infectious rhinitis within 4 weeks prior to the screening
•Have malignant tumor

Related studies

RECRUITINGPhase 2

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

NCT07301736 · Asthma

Remote Anxiety Management for ICS-resistant Asthma Study

NCT06732141 · Asthma

RECRUITINGPhase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263 · Asthma

Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis

NCT07245576 · Asthma, COPD

Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

NCT07160868 · Asthma (Diagnosis), OSA - Obstructive Sleep Apnea, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 9, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment209

Start dateSep 2012

Last updatedDec 9, 2013

Condition

Locations shown

Ajou University Medical Center

Suwon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2013Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions